All In Biotech

Drug Trial Radar · NCT06727552

A Study of Barzolvolimab in Patients With Atopic Dermatitis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

131

Actual

Start

Dec 18, 2024

Primary completion

May 6, 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Celldex TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Conditions

  • Atopic Dermatitis

Interventions

  • BarzolvolimabBiological

    Subcutaneous Administration

  • Matching placeboDrug

    Subcutaneous Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from Baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16Time frame: From Day 1 (first dose) to Day 113 (week 16)

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center, LLC

    Birmingham, Alabama

  • Ohara Aivaz MD Dermatology

    Beverly Hills, California

  • Advanced Dermatology Center - Burbank

    Burbank, California

  • 310 Clinical Research

    Inglewood, California

  • Avance Trials

    Laguna Niguel, California

  • LA Universal Research Center, Inc.

    Los Angeles, California

  • UCLA Division of Dermatology

    Los Angeles, California

  • Dynasty Dermatology

    Pasadena, California

  • Acclaim Clinical Research

    San Diego, California

  • FOMAT Medical Research - Allergy, Asthma, & Immunology Medical Group

    Ventura, California

  • Focus Clinical Research

    West Hills, California

  • Direct Helpers Research Center

    Hialeah, Florida

  • International Dermatology Research Inc - Miami

    Miami Lakes, Florida

  • Sarasota Clinical Research

    Sarasota, Florida

  • Well Pharma Medical Research Corporation

    South Miami, Florida

  • Centricity Research Columbus Dermatology

    Columbus, Georgia

  • Georgia Skin and Cancer Clinic

    Savannah, Georgia

  • Treasure Valley Medical Research

    Boise, Idaho

  • Center for Medical Dermatology + Immunology Research

    Chicago, Illinois

  • Sneeze Wheeze and Itch Associates LLC

    Normal, Illinois

  • Equity Medical LLC

    Bowling Green, Kentucky

  • Allergy and Asthma Specialists PSC

    Owensboro, Kentucky

  • Onyx Clinical Research - Michigan

    Flint, Michigan

  • Revival Research Institute, LLC

    Troy, Michigan

  • Excel Clinical Research

    Las Vegas, Nevada

  • Equity Medical, LLC

    New York, New York

  • OptiSkin Medical

    New York, New York

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio

  • Palmetto Clinical Trial Services LLC

    Simpsonville, South Carolina

  • Zenos Clinical Research

    Dallas, Texas

  • Sienna Dermatology

    Sugar Land, Texas

  • Center for Clinical Studies LTD.LLP

    Webster, Texas

  • Jordan Valley Dermatology Center - South Jordan

    South Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.